Article
SRGN-Triggered Aggressive and Immunosuppressive Phenotype in a Subset of TTF-1-Negative Lung Adenocarcinomas.
Journal of the National Cancer Institute - 7 Feb 2022
Tanaka Ichidai, Dayde Delphine, Tai Mei Chee, Mori Haruki, Solis Luisa M, Tripathi Satyendra C, Fahrmann Johannes F, Unver Nese, Parhy Gargy, Jain Rekha, Parra Edwin R, Murakami Yoshiko, Aguilar-Bonavides Clemente, Mino Barbara, Celiktas Muge, Dhillon Dilsher, Casabar Julian Phillip, Nakatochi Masahiro, Stingo Francesco, Baladandayuthapani Veera, Wang Hong, Katayama Hiroyuki, Dennison Jennifer B, Lorenzi Philip L, Do Kim-Anh, Fujimoto Junya, Behrens Carmen, Ostrin Edwin J, Rodriguez-Canales Jaime, Hase Tetsunari, Fukui Takayuki, Kajino Taisuke, Kato Seiichi, Yatabe Yasushi, Hosoda Waki, Kawaguchi Koji, Yokoi Kohei, Chen-Yoshikawa Toyofumi F, Hasegawa Yoshinori, Gazdar Adi F, Wistuba Ignacio I, Hanash Samir, Taguchi Ayumu
Abstract excerpt
BACKGROUND: Approximately 20% of lung adenocarcinoma (LUAD) is negative for the lineage-specific oncogene Thyroid transcription factor 1 (TTF-1) and exhibits worse clinical outcome with a low frequency of actionable genomic alterations. To identify molecular features associated with TTF-1-negative LUAD, we compared the transcriptomic and proteomic profiles of LUAD cell lines. SRGN , a chondroitin sulfate...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
